Benzinga

Benzinga Korea 한국

Benzinga

Benzinga Korea 한국

Benzinga

Benzinga Korea 한국
금요일, 8월 28

Legend Biotech Corp

LEGNNASDAQ
Trade with Public
Trade with Public
$20.50
-0.18-0.87%
가까이에: Aug 27, 5:00 PM EST
$20.60
0.100.49%
시간외: 6:27 PM EST
개요뉴스실적 전망이벤트목표가재무심리지분 현황비교옵션주식 보고서

Legend Biotech Financials

Legend Biotech (LEGN) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Legend Biotech Q2 Adj. EPS $0.16 Beats $0.07 Estimate, Sales $387.500M Beat $355.772M Estimate

Legend Biotech (NASDAQ:LEGN) reported quarterly earnings of $0.16 per share which beat the analyst consensus estimate of $0.07 by 100 percent. This is a 147.06 percent increase over losses of $(0.34) per share from the
Benzinga Newsdesk

These Analysts Revise Their Forecasts On Legend Biotech After Q1 Results

Legend Biotech (LEGN) reported Q1 losses of 3 cents per share and sales of $305.1 million, missing estimates. Stock rose 1.3% to $28.63. Analysts maintained ratings and adjusted price targets.
Avi Kapoor

Earnings Scheduled For May 12, 2026

Benzinga Insights

PRO
Legend Biotech Q1 Adj. EPS $(0.03) Misses $(0.02) Estimate, Sales $305.100M Miss $307.035M Estimate

Legend Biotech (NASDAQ:LEGN) reported quarterly losses of $(0.03) per share which missed the analyst consensus estimate of $(0.02) by 50 percent. This is a 57.14 percent increase over losses of $(0.07) per share from the
Benzinga Newsdesk

Earnings Scheduled For March 10, 2026

Benzinga Insights

Legend Biotech Q4 Earnings Summary & Key Takeaways

Benzinga Insights

데이터 및 API: Benzinga API · 주식 뉴스 API · 애널리스트 등급 API · 회사 로고 API

Benzinga

Benzinga Korea 한국

뉴스

파트너 / 기고자

벤징가 글로벌

© 2026 Benzinga | All Rights Reserved